Clinical TrialJul 27, 2026, 07:11 AM
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results
AI Summary
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease. The company conducted a repeat 13-week toxicology study in rats, which showed no unexpected adverse findings, addressing previous discrepancies. Based on these results, Neumora plans to submit an Investigational New Drug (IND) application in the fourth quarter of 2026 and initiate a Phase 1 clinical study by the end of 2026.
Key Highlights
- Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215.
- Company plans to submit an IND application for NMRA-215 in Q4 2026.
- Neumora aims to initiate a Phase 1 study for NMRA-215 by the end of 2026.
- NMRA-215 is a highly brain-penetrant, oral NLRP3 inhibitor for obesity and cardiometabolic disease.
- A repeat 13-week rat toxicology study with 162 animals showed no unexpected adverse findings.
- Prior adverse findings in an earlier study were attributed to discrepancies, not NMRA-215.
- NMRA-215 demonstrated class-leading weight loss as monotherapy in pre-clinical models.
Price Impact
More from NMRA